Clarivate Epidemiology’s coverage of cancer pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of cancer pain for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s cancer pain forecast will answer the following question:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of cancer pain over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts seven cancer pain patient populations, as follows:
Total prevalent cases of severe cancer pain.
Total prevalent cases of breakthrough cancer pain.
Total prevalent cases of neuropathic cancer pain.
Total prevalent cases of tumor-related neuropathic cancer pain.
Total prevalent cases of chemotherapy-related neuropathic cancer pain.
Total prevalent cases of neuropathic cancer pain that is related to other causes.
Literature review (studies included in/excluded from the analyses of cancer pain)
Total prevalent cases of severe cancer pain
Total prevalent cases of breakthrough cancer pain
Total prevalent cases of neuropathic cancer pain
Total prevalent cases of neuropathic cancer pain by subtype
Total prevalent cases of metastatic bone pain
Risk / protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation table
Prashant Kumar
Prashant Kumar, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, he coordinated various public health projects focused on tuberculosis, COVID, and malnutrition. He also has experience working in the health insurance domain in India, where he was involved in claims data analytics and stakeholder management. He holds an M.P.H specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai.
Shilpa Thakur
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
